🔗 Share this article

As the US continues making unprecedented changes to its vaccine schedules, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has concentrated on alleged deaths after Covid vaccination in her short tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders had intended to reveal major revisions to the childhood vaccination calendar recently, aligning the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with many the world with insufficient data for improved outcomes. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A New Direction at the FDA

The acting appointment might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending specific pediatric vaccine recommendations in the US to become more like the Danish model, a nation with universal health coverage and a citizenry about the population of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Qualifications

The appointee has no obvious track record in drug development, regulation or leadership, which has been typical for former heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a major agency. She lacks background in pharmaceutical oversight.”

Former directors of CBER would “grasp laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who led CBER have had.”

This division has an immense workload at the FDA, she pointed out.

“Many people just pays attention on the novel medication approvals, but the generic program clears thousands of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and each of these have to be managed,” Woodcock explained. “The area you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a significant management element to the position, which manages over 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” the former official added.

Official Statement and Disputed Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among FDA leaders on vaccines, a press secretary stated that the “questions stem from inaccurate presumptions”.

“Her experience aligns with the functions of her job,” the spokesperson explained, pointing to the months Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial rapid medication authorization process that allegedly concerned her predecessors. “By what process are these medications being chosen for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the FDA seems to be moving towards more relaxed rules of all drugs, with the exception of immunizations.”

Established Track Record on Immunizations

With vaccines, Høeg has a clearer, if problematic, history, critics have noted. She published a research paper using non-validated public submissions to estimate the frequency of myocarditis after COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the new federal leadership included revising rules for novel immunizations and discontinuing “optional” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly proposed barring young men from receiving COVID-19 vaccinations.

“She is an complete ideologue who commences with her beliefs and tailors the evidence to accommodate the data in a highly disingenuous, untruthful way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|